Earnings call transcript: Medifast Q3 2025 shows revenue decline, stock dips

Medifast Inc. (MFST) reported its third-quarter 2025 earnings, revealing a revenue of $89.4 million, which represents a 36.2% decrease year-over-year. The company reported a net loss of $2.3 million, translating to a loss of $0.21 per diluted share. These results surpassed the forecasted EPS loss of $0.3, though revenue fell short of the anticipated $93.8 million. Following the earnings release, Medifast’s stock price decreased by 1.21% in after-hours trading, closing at $12.02, nearing its 52-week low.

Key Takeaways

• Medifast’s Q3 2025 revenue decreased by 36.2% year-over-year.
• The company reported a net loss of $2.3 million, or $0.21 per share.
• Stock price declined by 1.21% in after-hours trading.
• Active OPTAVIA coaches decreased by 35% year-over-year.
• New product line focused on metabolic health set to launch in 2026.

Company Performance

Medifast experienced a significant decline in both revenue and active earning coaches during Q3 2025. The revenue drop of 36.2% year-over-year is attributed to a decrease in the number of active OPTAVIA coaches by 35%. The company is repositioning itself from a weight loss company to a leader in metabolic health, which may impact its future performance.

Financial Highlights

• Revenue: $89.4 million (36.2% decrease YoY)
• Earnings per share: -$0.21 (exceeded forecast of -$0.3)
• Gross profit margin: 69.5% (590 basis point decrease)
• Cash and investments: $173.5 million

Earnings vs. Forecast

Medifast reported an EPS of -$0.21, surpassing the forecasted EPS of -$0.3, marking a 30% positive surprise. However, revenue fell short, coming in at $89.4 million against the forecasted $93.8 million, a miss of 4.69%.

Market Reaction

Following the earnings announcement, Medifast’s stock fell by 1.21% in after-hours trading, closing at $12.02. The stock is trading close to its 52-week low of $11.57, reflecting investor concerns over the company’s declining revenue and active coach numbers.

Outlook & Guidance

Looking ahead, Medifast provided guidance for Q4 2025, forecasting revenue between $65 million and $80 million, and an EPS range of -$0.70 to -$1.25. The company plans to launch a new product line focused on metabolic health in 2026, aiming to capture a broader market beyond weight loss.

Executive Commentary

CEO Dan Chard stated, "We are evolving Medifast from being seen primarily as a weight loss company to one that is recognized as a leader in the broader field of metabolic health." He emphasized the company’s commitment to long-term sustainable growth through strategic initiatives.

Risks and Challenges

• Declining number of active coaches could impact future revenue.
• Intense competition in the weight loss and metabolic health markets.
• Economic challenges affecting consumer spending on health products.
• Potential risks associated with launching new product lines.

Q&A

During the earnings call, analysts inquired about the company’s strategies for training coaches in metabolic health and the impact of economic conditions on consumer priorities. The management addressed these concerns by highlighting ongoing enhancements to their digital platforms and leadership development programs.

Full transcript - MEDIFAST INC (MED) Q3 2025:

Conference Call Operator: Greetings and welcome to the Medifast Third Quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Steve Zenker, Vice President of Investor Relations. Thank you, sir. You may begin.

Steve Zenker, Vice President of Investor Relations, Medifast: Good afternoon and welcome to Medifast Third Quarter 2025 earnings conference call. On the call with me today are Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chief Financial Officer. By now, everyone should have access to the earnings release for the third quarter ended September 30, 2025, that went out this afternoon at approximately 4:05 P.M. Eastern Time. If you have not received the release, it is available on the Investor Relations portion of Medifast’s website at www.medifastinc.com. This call is being webcast, and a replay will also be available on the company’s website. Before we begin, we would like to remind everyone that today’s prepared remarks contain forward-looking statements, and management may make additional forward-looking statements in response to your questions. The words believe, expect, anticipate, and other similar expressions generally identify forward-looking statements.

These statements do not guarantee future performance, and therefore undue reliance should not be placed on them. Actual results could differ materially from those projected in any forward-looking statements. All of the forward-looking statements contained herein speak only as of the date of this call. Medifast assumes no obligation to update any forward-looking statements that may be made in today’s release or call. Now, I would like to turn the call over to Medifast Chairman and Chief Executive Officer, Dan Chard.

Dan Chard, Chairman and Chief Executive Officer, Medifast: Thank you, Steve, and good afternoon, everyone. We appreciate you joining us today as we discuss our third quarter results and share an update on our progress. This is an important year for Medifast, one where the work we’ve done to transform the business is beginning to align more clearly with the opportunity we see in front of us. The weight loss and wellness industry has undergone fundamental change in a very short time. The rapid growth in consumer understanding and usage of GLP-1 medications has reshaped much of the public conversation around obesity and health, introducing millions of people to a tool for appetite control that leads to weight loss. While these medications are truly groundbreaking, they are not a complete solution to long-term health unless they are paired with lifestyle modifications.

Further, most weight challenges are rooted in poor metabolic health, also called metabolic dysfunction, which medication alone does not fully correct. A lifestyle approach that builds healthy habits and protects lean muscle mass during weight loss is essential to improving metabolic health. Since many people discontinue medication, the absence of these fundamental changes often leads to weight regain. For most people, the most durable path forward comes from addressing the underlying metabolic issues, not relying on medication alone. Data across multiple studies paint a consistent picture. Up to 40% of the weight lost while on GLP-1 medications comes from lean mass, including muscle. 74% of those on the medications discontinue them within a year, and the majority regain much of the weight they lost once they stop. For many, this leads to a cycle of temporary success followed by intense frustration.

The opportunity for Medifast is to help break that cycle, to empower people not just to lose weight, but to learn how to keep it off, and most importantly, to improve their metabolic health in the process, leading to a body that uses energy more efficiently, preserves muscle, and functions the way it was designed to. There is a significant opportunity in front of us to deliver a reset that helps the body work as it was meant to. More than 90% of US adults are metabolically unhealthy. This represents not only a vast health challenge but also a once-in-a-generation opportunity to redefine what wellness looks like. Our mission and our growth strategy are centered on meeting that need. Our clinically studied plan is designed to address the underlying causes of metabolic dysfunction, reducing bad visceral fat, retaining lean mass, and protecting healthy muscle, and helping improve overall body composition.

We don’t believe success should be measured just by pounds lost, but by how much healthier a person’s body becomes in the process. We recently announced clinical research findings led by our scientific and clinical affairs team using a science focused on metabolic synchronization, a breakthrough approach that reverses metabolic dysfunction with a targeted reset. Our most recent clinical analysis uncovered findings that revealed that our comprehensive plan delivers strong and targeted fat burn, resulting in not only weight loss but also improved body composition. At 16 weeks, clients on our plan retained 98% of their lean mass, reduced visceral fat by 14%, and showed measurable improvement in body composition while losing weight and protecting muscle. This reduction in visceral fat, the bad fat driving metabolic dysfunction, along with strong muscle preservation, are key indicators of improved metabolic health.

Whether a client is using a GLP-1 medication, transitioning off one, or not using one at all, our program provides a foundation for overall metabolic health and well-being. This is not just a short-term fix but a comprehensive system that is specifically designed to help people live a healthier life. At the center of our approach is the human connection provided by our incredible coaches. These coaches play a vital role in translating the underlying science that powers our approach into real-world results that help people make a real difference in their approach to health. Coaches’ understanding of the benefits and shortcomings of GLP-1 medications continues to build all the time. Currently, 61% of our coaches have already worked with clients who are using GLP-1 medications, and 22% of our client base reports either using or having tried a GLP-1 medication in the past year.

That gives us invaluable insight into how these medications are being used and how our approach can complement them. Medications alone are simply not enough in our view. Clinical data shows that clients who work with a coach lose 10 times more weight and 17 times more fat than those who go it alone. That’s certainly not a coincidence. Our coaches guide clients through the important behavioral and nutritional lifestyle changes needed to maintain their progress on their health journey. The coaches help people stay accountable, navigate challenges, and build the healthy lifestyle habits that lead to lasting results. Coaching is what makes the difference between temporary change and long-term transformation. We’re evolving Medifast from being seen primarily as a weight loss company to one that is recognized as a leader in the broader field of metabolic health.

It’s a shift to a far larger and more durable market as we move from helping people not only lose weight but also helping them live metabolically healthier lives. Looking ahead, the company plans to launch significant product innovations using the science of metabolic synchronization and incorporating next-generation ingredients for metabolic enhancement. Initial feedback from the field of coaches has shown encouraging results, and we expect to bring this new product line to market next year. This new product line builds on the strength of our existing programs, and we believe it will further differentiate Medifast in the marketplace. Our aim is not just to respond to the rise of GLP-1s but to define what the next generation of metabolic health solutions will look like, combining clinical credibility, human connection, and healthy results. To deliver further on our ambitions in the metabolic health space, we’re moving forward on several fronts.

Our coach leaders have already been trained on the new clinical data, and they are now cascading that knowledge throughout their organizations. This training will continue into 2026 as coaches learn to reach new types of clients, people who are focused not just on weight loss but also on their overall metabolic health. We are seeing continued momentum in our work to support our coaches and clients. The new Premier Plus pricing and auto-ship program has simplified our value proposition, creating a more consistent experience for both coaches and clients. It offers immediate savings, predictable pricing, and a straightforward path to loyalty, making it easier for coaches to attract and retain clients. While it’s still early, we’re encouraged by the initial response, which has shown an uptick in baseline client retention beyond the first month.

We’ve also continued to strengthen the leadership foundation of our field through our Edge Leadership Development Program. Edge combines incentives, best practices, and recognition tools to help coaches grow their businesses with purpose and structure. The program was built in partnership with field leaders, ensuring it reflects real-world experience. It’s designed to make early success achievable and sustainable, helping new coaches find their footing and build confidence, and enabling our experienced coaches to scale their impact. In a world where technology increasingly replaces human interaction, our greatest strength remains the power of personal connection, and we’re continuing to focus on how we take full advantage of our highly personalized solution. Both Premier Plus and Edge are important components of our commercial model, and we expect these to play a central role in continuing to improve coach productivity and stability as we move into 2026.

In the third quarter, productivity among active coaches continued to show signs of stability. We’re also continuing to invest in our digital platforms to make the coaching and client experience even more seamless. Enhancements to our app and reporting tools are providing better visibility into client progress and coach performance, giving our field more actionable insights and allowing them to focus where they can make the biggest impact. Regarding our third-quarter results, revenue of $89 million for our third quarter was at the high end of our guidance range, and EPS came in within our guidance range. Active earning coach productivity for the quarter of $4,585 was down just 2% year over year, continuing a trend of moderating declines. Sequentially, coach productivity was down 1%. As we look ahead, our strategy remains clear. We’re building Medifast as a science-backed coach-guided system for promoting long-term metabolic health.

The trends shaping this industry, from medical intervention to lifestyle integration, point towards the need for exactly what we offer: a system that helps people improve their metabolic function by getting rid of the bad fat, preserving lean mass, and protecting their muscle, ultimately empowering them to healthier results over time. We’ve already taken important steps to position the business for this future. Our transformation is not theoretical. It’s visible in the way our coaches are working, in the science behind our products, and in the foundation we’re laying for the next phase of growth. We have more work to do. We’re confident in our direction. We have a strong balance sheet, no debt, and more than $170 million in cash and investments.

We have a passionate coach community that continues to adapt and lead, and we have a comprehensive program, plan, and product that are scientifically validated and aligned with where we believe consumer demand is headed. We’re a company that has been built on ongoing innovation and that is always thinking about the next chapter. We expect that the foundation we’re building today will redefine what health looks like for the years to come. By combining our science, our coaches, and our community, we are positioning Medifast to become the trusted partner for millions of people seeking to improve metabolic health. We’re building for long-term sustainable growth, and we’re doing that with discipline and conviction. Now I’ll turn it over to Jim to review the finances and our outlook for the next quarter.

Steve Zenker, Vice President of Investor Relations, Medifast: Thank you, Dan. Good afternoon, everyone. As Dan mentioned earlier, third-quarter 2025 results for both revenue and EPS were at the high end of our guidance ranges. Revenue for the third quarter was $89.4 million, a decrease of 36.2% versus the year earlier period, primarily due to a decrease in the number of active earning OPTAVIA coaches. We ended the quarter with approximately 19,500 active earning OPTAVIA coaches, a decrease of 35% from the third quarter of 2024. Average revenue per active earning OPTAVIA coach for the third quarter was $4,585, a year-over-year decrease of 1.9%, primarily driven by continued pressure on client acquisition. We continue to see moderating year-over-year declines in this key metric. Gross profit decreased 41.2% year-over-year to $62.2 million, driven by lower sales volumes, partially offset by lower cost of sales.

Gross profit margin for the current quarter was 69.5%, which decreased 590 basis points compared to the year earlier period, attributable to 450 basis points of loss of leverage on fixed costs and 180 basis points of a reserve for the reformulation of the Essential product line. As Dan mentioned, we expect to introduce a new product line next year, which is intended to improve upon the effectiveness of our current Essential product line in addressing overall metabolic health. These new products will replace the current Essential line of fuelings that are part of many of our current plans. SG&A expense was down 36% year-over-year to $66.2 million, primarily due to a $19.7 million decrease in coach compensation on fewer active earning coaches and lower volumes.

Additionally, SG&A expenses in the current quarter reflected decreases of $5.6 million related to company-led marketing compared to 2024, as well as $2.9 million for the company’s convention cost and $2 million for the company’s collaboration with LifeMD that did not recur in the current quarter. SG&A, as a percentage of revenue, increased 20 basis points, primarily due to approximately 520 basis points associated with the loss of leverage on fixed cost and other smaller increases, partially offset by a 360 basis point reduction related to company-led marketing and 210 basis points for the company’s convention cost incurred in the prior year’s comparable period that did not recur in the third quarter of 2025. Loss from operations was $4.1 million in the third quarter of 2025 compared to income from operations of $2.1 million in the prior year comparable period.

As a percentage of revenue, loss from operations was 4.6% in the third quarter compared to income from operations of 1.5% in the prior year period. Other income increased $2 million year-over-year to $1.4 million, primarily due to a loss on the company’s investment in LifeMD’s common stock during the corresponding period in 2024. As you may recall, we sold the investment in the second quarter 2025. The effective tax rate was 14.9% for the third quarter of 2025 compared to 28.5% in the prior year period. The change in the effective tax rate for the three months ended September 30, 2025, was primarily driven by a decrease in the tax benefit of research and development tax credits, which represented 115.3% of the change, partially offset by an increase of 85.6% from the impact of state taxes. These percentages were magnified by the near-break-even pre-tax position in the current year.

Net loss in the third quarter of 2025 was $2.3 million, or $0.21 loss per diluted share, compared to net income of $1.1 million, or $0.10 per share in the year earlier period. Our financial position remained strong with $173.5 million in cash, cash equivalents, and investments, and no interest-bearing debt as of September 30, 2025. Now I’ll turn it to guidance. We are expecting fourth-quarter revenue to range from $65-$80 million and a loss per share for the quarter ranging from $0.70-$1.25. With that, let me turn the call back to the operator for questions.

Dan Chard, Chairman and Chief Executive Officer, Medifast: Thank you. We will now be conducting a question-and-answer session. If you would like to ask a question, please press Star 1 on your telephone keypad. A confirmation tone will indicate that your line is in the question queue. You may press Star 2 if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the Star keys. One moment, please, while we pull for questions. Our first question comes from Jim Solari with Stevens. Please proceed with your question.

Hey, guys. Good afternoon. Thanks for taking our question. I wanted to first start with the shifting focus towards metabolic dysfunction and how integrating that messaging with the coaches is going to work. Can you just maybe walk us through the process to make sure that you have consistent messaging among the coaches and that they’re all kind of trained up on the new go-to-market or strategy around communicating the kind of holistic view that you guys are taking to weight loss moving forward?

Sure, Jim. Let me also start out by adding that Nick Johnson, our Chief Field Operations Officer and President of OPTAVIA, has joined us as well. I’ll make a couple of comments, and then I’ll let him talk about what we’re doing to make sure that the coaches across the entire country are trained and understand what this new story around metabolic health is. I mean, I’ll start out by saying that most weight loss challenges and 9 out of 10 of the leading health challenges for the country are rooted in poor metabolic health, or that’s sometimes referred to as metabolic dysfunction. Our coaches are aware of this, so it starts out by partially an awareness.

What we’ve done, probably in the most significant way we ever have, is conducted a study partially tied to previous research that we’ve done, but also taking a deeper dive into the clinical studies to show exactly what our program does with metabolic health and how it is able to reverse metabolic dysfunction. Here’s how it links to weight loss. We talked a little bit about some of these claims or the results of our study in the last call, but I’ll just cover them again. The first and significant one is our program targets the bad fat, or often referred to as visceral fat, and that’s the fat around the belly and inside and around vital organs. It reduces that fat at a clinically significant level. It maintains lean mass in 98% during weight loss. It protects muscle and improves body composition.

You’ve heard us talk about the other part of our research that shows that when a coach gets involved in helping somebody on the program, the clients are able to lose 10 times more weight and 17 times more fat. Those are new claims that we’ve shared with our coaches. The important part of what they’re doing now is the targeting, which is fairly expansive. 90% of Americans are metabolically unhealthy or experience metabolic dysfunction. With our research, this clinical research, and an understanding of how we can reverse that, they have an interesting and highly relevant new story.

It’s becoming increasingly relevant even in the face of this world where GLP-1 drugs have had such an impact on people trying them, which is that basically our program is differentiated in that we maintain 98% of lean body mass, whereas GLP-1 drugs often result in as much as 40% of the weight loss being from lean mass and high levels of discontinuation. 74% of patients discontinue use within a year of GLP-1 drugs, and two-thirds of the weight is regained. That’s kind of the problem-solution, if you will. Now let Nick talk a little bit about how we are training leaders and how that leadership base now is in the process of training the field. Turn some time over to Nick to do that.

Nick Johnson, Chief Field Operations Officer and President of OPTAVIA, Medifast: Thanks, Dan. Recently we met with all of our leaders at a retreat, our annual leadership retreat that took place in Sundance, Utah. All of those lines of business across our business were actually represented. With all the leaders of the different lines of business now informed, trained, and understanding where we’re going in the direction of metabolic synchronization, our proprietary science that addresses and reverses metabolic dysfunction. From now until the end of the year, those messages, those trainings will continue to be disseminated. By the end of the year, we expect to have all of the different coaches all the way down to our core rank of executive director trained and steeped in this direction. We ensure that we are across the network singing from the same song sheet, so to speak.

Great. That’s very helpful. Can you speak to just the Edge program and maybe the incentive structure as, again, you kind of expand the aperture of the focus of what coaches are going to be communicating to potential clients? I would imagine that kind of broadens the range of potential clients they can talk to?

Dan Chard, Chairman and Chief Executive Officer, Medifast: Yeah, that’s another good one for Nick. So Nick, why don’t you take that one as well?

Nick Johnson, Chief Field Operations Officer and President of OPTAVIA, Medifast: Sure thing. As we’ve talked about in the past, the Edge program is designed around really three activities, and they’re all based on the same core rank, Executive Director. It’s for creation of new Executive Directors, duplication of those directors, and then multiplication of those Executive Directors. The Edge program is designed to change the rank composition of the business. Now, keep in mind that those Executive Directors have approximately $6,000 in revenue per Executive Director. They’re highly, highly productive. When we see the rank composition of the business start to shift in a more positive direction, revenue and therefore productivity go up as the rank composition improves. We’ll continue to focus on the Edge program. Like we said in the past, focusing on becoming and duplicating and multiplying those Executive Directors.

What we discussed at the Sundance leadership retreat is how we will continue to execute the Edge program, which will then yield that higher productive coach rank and then fill out the different generations within the pay structure for our top leaders.

That’s helpful. Maybe shifting gears a little bit, Jim, just a couple of questions on the guidance and then some of the results in the quarter. Maybe for starters, it looks like you closed the gap between the decline in SG&A and the decline in the top line. Those are much more kind of aligned than in previous quarters. I appreciate you gave some detail around maybe some one-time expenses there. Can you just give us some color around, is there a way we should think about if the top line’s down X percent, SG&A should underperform that by 100 basis points, 200 basis points, just as we think about kind of modeling that on a go-forward basis?

Steve Zenker, Vice President of Investor Relations, Medifast: Yeah. I mean, as you mentioned, one of the charges in Q3 was an approximate $1.5 million charge for the reformulation of our Essential line. So we made the decision in Q3 of 2025, so we took that charge. We believe that’s going to be a one-time item. We also mentioned regarding within gross margin that we had a loss of leverage of fixed cost. And what we have done and what we continue to do is make sure that our balance sheet remains strong, excuse me, for the foreseeable future. We ended the quarter with $170 million in cash and investments, and we’re right-sizing the business. We did some actions in October, so last month, to right-size the business to make sure that as we return to growth, the margins will improve.

When you look at our guidance, you mentioned guidance, and we are seeing pressure continue into Q4 with the guidance that we provided. As I mentioned before on our call, the way our business works and the way we get back to growth, looking at our metrics, our expectations are that it starts with client acquisition and client retention. Based on the history, when we get growth in revenue per active earning coach and a sustained improvement in revenue per active earning coach, the growth of it, typically we see about six to nine months after that, we typically see coach growth. Obviously, once we get back to coach growth is when you get back to revenue growth, probably within a quarter or two from that coach growth.

We’ve been mentioning to investors, and I believe we mentioned it on our last call, that we’re anticipating that to happen in 2025. We are anticipating that to happen in Q4, but at a minimum, getting back to revenue per active earning coach growth, we believe will happen at least in the next six months. We’re expecting it to happen in Q4, and that’ll be the first green shoot of stabilization for the company and a path forward to get back to growth. We’re anticipating that happened in Q4, but at a minimum in the next six months.

Okay. Maybe on the top line, can you just speak to any, outside of obviously GLP-1 kind of well-covered trends, just broader economic softness and softness we’ve seen in the consumer? Just any commentary you can offer on how that’s been impacting the likelihood of consumers to add an incremental monthly expense like OPTAVIA into their budget?

Dan Chard, Chairman and Chief Executive Officer, Medifast: Go ahead, Dan. I was going to say, one of the things we continue to see, Jim, and this is not something that’s new, but consumers prioritize their health. This is a health issue that’s been with us for quite some time and is not relenting. We have high satisfaction with those clients who choose to engage in our program, as evidenced by their high repeat. I think we always are looking at what you’re asking about, which is, does a challenged economy affect consumer spending? I think certainly the answer is yes, but we continue to see consumers prioritizing their spend on health over other things. I think we feel optimistic about where we are. I think we’ve changed the value equation to be even more significant with these additional kind of insights into just how our program affects the end consumer.

We see our coaches getting better and better at operating in this current environment. As I said in the prepared remarks, we have now over 60% of our coaches who are supporting at least one client who is either on or who has been on a GLP-1 drug. 22% of our client base either using or having used GLP-1 drugs. We see our program as valuable in the current environment and relevant for people who are using a GLP-1 drug and want a lifestyle program, who want to do it without a GLP-1 drug because they don’t want to or have a negative reaction to the medication, or increasingly people who are transitioning off and want to make sure that they can maintain the health of the gain.

Now there’s one more reason for those who want to get to really the root of some of these symptoms of metabolic dysfunction and really focus on the source of the challenge and achieve this lifelong transformation that our coaches have been talking about for quite some time.

Got it. And then maybe just one housekeeping question. Jim, I think you had mentioned when you were kind of breaking down the SG&A expenses that you guys were cycling. There was a $2 million, I think you said $2 million. For collaboration with LifeMD. I just want to make sure, is that something that was a one-time expense last year that we’re lapping, or are you guys sunsetting the LifeMD partnership, and that’s on a go-forward basis that’s coming out of SG&A?

Steve Zenker, Vice President of Investor Relations, Medifast: No, the collaboration is ongoing. What that is, is that was the last. In 2024, that $2 million was the last bit of amortization. If you remember, at the beginning of our collaboration, we invested $10 million into LifeMD as part of the collaboration. And that $2 million in Q3 of 2024 represented the last bit of the amortization. So we took the $8 million prior to that. You won’t see that any longer.

Got it. That’s helpful. I appreciate all the commentary. I’ll hop back in with you.

Conference Call Operator: We have reached the end of our question and answer session. There are no further questions at this time. I would now like to turn the floor back over to Dan Chard for closing comments.

Dan Chard, Chairman and Chief Executive Officer, Medifast: Thanks, everybody, for joining the call today. This continues to be a period of meaningful transformation, as you could hear, for the company. We are evolving with purpose to become a science-backed, coach-led leader in metabolic health. Our approach, built around the science of metabolic synchronization, enables us to target better health rather than just weight loss, reducing visceral fat while preserving lean mass. We are very encouraged by the progress that we are making, from the stabilization of coach productivity to advancing new product innovation and digital tools. We remain confident in our strategy, supported by a strong balance sheet and a dedicated coach community focused on long-term client success. I look forward to sharing even more when we present at the Stevens Annual Investment Conference on November 19th in Nashville. Thanks again for joining us today and for your continued interest in Medifast.

Conference Call Operator: This concludes today’s teleconference. You may disconnect your lines at this time. Thank you for your participation.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.